Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock

Critical Care Medicine

Volumn 38, Issue 6, 2010, Pages 1436-1441

  Calfee, Carolyn S ^a,b   Thompson, B Taylor ^c,d   Parsons, Polly E ^e   Ware, Lorraine B ^f   Matthay, Michael A ^a,b   Wong, Hector R ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Medicine   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lung injury; Interleukin 8; Negative predictive value; Risk stratification; Sensitivity; Speci ficity

Indexed keywords

BIOLOGICAL MARKER; HYPERTENSIVE FACTOR; INTERLEUKIN 8;

ACUTE LUNG INJURY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT; SEPTIC SHOCK;

EID: 77953081638     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de42ad     Document Type: Article

References (30)

1. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001; 134:663-694 (Pubitemid 32322245)
2. Altman DG: Statistics and ethics in medical research: III. How large a sample? BMJ 1980; 281:1336-1338
3. Glickman SW, McHutchison JG, Peterson ED, et al: Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009; 360:816-823
4. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-1636
5. Lemeshow S, Klar J, Teres D: Outcome prediction for individual intensive care patients: Useful, misused, or abused? Intensive Care Med 1995; 21:770-776
6. Marshall JC, Reinhart K: Biomarkers of sepsis. Crit Care Med 2009; 37:2290-2298
7. Marshall JC: Biomarkers of sepsis. Curr Infect Dis Rep 2006; 8:351-357
8. Dowsett M, Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14:8019-8026
9. Levitt JE, Gould MK, Ware LB, et al: The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med 2009; 24:151-167
10. Van der Kaay DC, De Kleijn ED, De Rijke YB, et al: Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 2002; 28:1606-1612
11. Vermont CL, Hazelzet JA, de Kleijn ED, et al: CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care 2006; 10: R33
12. Damas P, Canivet JL, de Groote D, et al: Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25:405-412
13. Bozza FA, Salluh JI, Japiassu AM, et al: Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care 2007; 11:R49
14. Wong HR, Cvijanovich N, Wheeler DS, et al: Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178:276-282
15. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
16. The Acute Respiratory Distress Syndrome Networ: Higher versus lower positive endexpiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327-336
17. The Acute Respiratory Distress Syndrome Network: Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1-6
18. Parsons PE, Eisner MD, Thompson BT, et al: Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33:1-6; discussion 230-232
19. Calfee CS, Eisner MD, Ware LB, et al: Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007; 35:2243-2250
20. Flori HR, Glidden DV, Rutherford GW, et al: Pediatric acute lung injury: Prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 2005; 171:995-1001
21. Zimmerman JJ, Akhtar SR, Caldwell E, et al: Incidence and outcomes of pediatric acute lung injury. Pediatrics 2009; 124: 87-95
22. Watson RS, Carcillo JA, Linde-Zwirble WT, et al: The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701
23. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
24. Prendergast TJ, Luce JM: Increasing incidence of withholding and withdrawal of life support from the critically ill. Am J Respir Crit Care Med 1997; 155:15-20
25. Cook D, Rocker G, Marshall J, et al: Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit. N Engl J Med 2003; 349:1123-1132
26. Darbonne WC, Rice GC, Mohler MA, et al: Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest 1991; 88:1362-1369
27. Cepkova M, Brady S, Sapru A, et al: Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care 2006; 10:R126
28. Baldessarini RJ, Finklestein S, Arana GW: The predictive power of diagnostic tests and the effect of prevalence of illness. Arch Gen Psychiatry 1983; 40:569-573
29. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
30. Ridker PM, Danielson E, Fonseca FA, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207